IO Frontiers World 2019

Japan Symposium


PLENARY Session : Wednesday, January 24, 2018


Japan has a fully integrated plan to advance and accelerate regenerative medicine products. Key Japanese leaders from academia, industry and government will present at this must-attend for anyone seeking to gain first-hand knowledge and insight into what is happening in Japan.

Chair’s Introduction: Takashi Asada, PhD, Professor, Kyoto University

Symposium Overview: Norio Nakatsuji, Professor Emeritus, Kyoto University and Chief Advisor, Stem Cell & Device Lab., Inc.

Keynote Address from Academia: Hideyuki Okano, MD, PhD Professor, Keio University Medical School; Director of the Japanese Society for Regenerative Medicine (JSRM)

Regulator’s Perspective: Yoji Sato, PhD, Head, Division of Cell-Based Therapeutic Products, National Institute of Health Sciences (Japan)

Industry Keynote Address: Akihiko Iwai, PhD Vice President, Astellas Pharma, Inc.; Vice Chairman, Forum for Innovative Regenerative Medicine (FIRM)

Masato Ibuki, Regenerative Medicine and Cell Therapy Laboratories, KANEKA Corporation

Masayo Yumoto, PhD, Group Leader, Basic Research Group, Regenerative Medicine Research & Planning Division, Rohto Pharmaceutical, Co., Ltd

Regenerative Medicine CMOs in Japan

A recent conversation with long-time Phacilitate collaborators and Japanese sector experts, CJ Partners, highlighted the quite extraordinary recent growth in the Japanese specialist CMO market – but nowhere else could we find a definitive list of the players in this rapidly evolving sector and their capabilities. With manufacturing such a critical and complex component for any cell & gene therapy company seeking to develop and commercialise in Japan, we felt it was high time someone put together a definitive, up-to-the-minute list of the specialist CMO options available across the nation to serve as a reference point for the global sector.

We hope you enjoy this unique infographic!

Regenerative Medicine CMO in Japan

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy